Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier.

Legend Biotech’s latest earnings and leadership change in July have come against a mixed share price backdrop, with a 1-year total shareholder return that declined 38.5% and a 3-year total shareholder return that declined 68.3%. Meanwhile, the year-to-date share price return is up 1.9%, hinting at early signs of stabilising momentum after a tougher multi year period.

If you are looking beyond Legend Biotech for other potential ideas in this area, now could be a good time to review a curated list of healthcare focused AI opportunities through the 42 healthcare AI stocks

Legend Biotech has shifted from losses to quarterly profit while the share price is still well below past levels. Does that mismatch leave more upside for new buyers, or does recent strength already capture the turnaround story?

Most Popular Narrative: 59.6% Undervalued

The most followed narrative on Legend Biotech pegs fair value at $54.23, compared with the last close at $21.92. That gap reflects a view that the current share price does not fully reflect the company’s projected revenue, earnings, and margin path.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.

Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that $54.23 figure. The narrative ties together growth in multiple myeloma, expansion into new geographies, and a specific profit profile to arrive at its fair value path.

Result: Fair Value of $54.23 (UNDERVALUED)

However, Legend Biotech’s reliance on CARVYKTI, along with the potential for rising competition or pricing pressure, could quickly challenge the upside case that many analysts are leaning on.

Next Steps

With both risks and rewards in play for Legend Biotech, it makes sense to move quickly and test the narrative against the underlying data yourself. To weigh those red flags against the potential upside in a single view, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Legend Biotech?

If Legend Biotech has sharpened your interest, do not stop here. Use the Simply Wall Street screener to uncover other stocks that match your approach.

• Target reliable cash generators by checking companies that pass the solid balance sheet and fundamentals stocks screener (50 results) and may better align with your comfort on financial strength.
• Hunt for potential value opportunities using the screener containing 20 high quality undiscovered gems before they appear on everyone else’s radar.
• Prioritise capital preservation and steadier price moves by reviewing the 79 resilient stocks with low risk scores that could fit a more cautious portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.